BioTuesdays

Tag - Jason McCarthy

Heat Biologics

Maxim starts Heat Biologics at buy; PT $1

Maxim Group launched coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and price target of $1. The stock closed at 26 cents on Feb. 5. Heat is developing lead asset, ImPACT, a cell-based immune therapy for...

Armata Pharmaceuticals

Maxim starts Armata Pharma at buy; PT $8

Maxim Group initiated coverage of Armata Pharmaceuticals (NYSE American:ARMP) with a “buy” rating and $8 price target. The stock closed at $3.71 on Feb. 5. Armata is developing phage therapies for the treatment of...

Cassava Sciences

Maxim ups Cassava Sciences PT to $12 from $3

Maxim Group raised its price target for Cassava Sciences (NASDAQ:SAVA) to $12 from $3, citing the recent rise in the company’s share price. The stock closed at $7.93 on Jan. 9. “Cassava’s shares have risen significantly...

Adamis Pharma

Maxim cuts Adamis Pharma to hold; withdraws PT

Maxim Group downgraded Adamis Pharmaceuticals (NASDAQ:ADMP) to “hold” from “buy” and withdrew its previous $3 price target after the company received a complete response letter (CRL) from the FDA regarding the NDA for...

SELLAS Life Sciences Logo

Maxim ups SELLAS to buy; sets PT $12

Maxim Group upgraded SELLAS Life Sciences (NASDAQ:SLS) to “buy” from “hold” with a price target of $12 after the company removed a financing overhang. The stock closed at $6.17 on Nov. 14. SELLAS ended the latest...

INmune Bio

Maxim starts INmune Bio at buy; PT $13

Maxim Group launched coverage of INmune Bio (NASDAQ:INMB) with a “buy” rating and $13 price target. The stock closed at $7.73 on March 18. INmune Bio is a clinical-stage immunotherapy company with three drug programs...

Matinas Biopharma

Maxim cuts Matinas BioPharma PT to $4 from $6

Maxim Group lowered its price target for Matinas BioPharma (NYSE American:MTNB) to $4 from $6, citing dilution from the company’s next financing. The stock closed at 68 cents on April 20. Analyst Jason McCarthy writes...

SELLAS Life Sciences Logo

Maxim ups Sellas Life Sciences to buy; PT $13

Maxim Group upgraded Sellas Life Sciences (NASDAQ:SLS) to “buy” from “hold,” with a $13 price target after meeting with Sellas management. The stock closed at $4.79 on March 16. Sellas completed a merger with Galena...

Maxim lowers BioLineRx PT to $2 from $3

Maxim Group reduced its price target for BioLineRx (NASDAQ:BLRX) to $2 from $3 after the company reported fourth quarter results. The stock was quoted at $1 in afternoon trading on March 6. BioLineRx, which focuses on...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.